Novel drug approvals head for a down year
With only 18 novel drugs approved by the FDA so far this year, the influential US regulator looks set to dim the green lights in 2019.
Upcoming events – Protagonist and Pfizer target rare diseases
Protagonist Therapeutics and Pfizer will soon get an idea of their respective chances in beta-thalassaemia and Duchenne muscular dystrophy.
Scholar thinks Glaxo made a wise move to back Merck
Scholar Rock selects a lead molecule inhibiting TGF-β, an increasingly important oncology mechanism that Glaxosmithkline recently paid €300m to enter.
Smaller groups await Bristol-Myers Squelgene fallout
Celgene had many fingers in many pies – so what will happen now to its smaller collaborators?
Bristol-Myers Squelgene makes its pre-JP Morgan splash
The New Year is not yet three days old, but deal-hungry investors looking forward to next week’s JP Morgan conference already have a megamerger on their hands.
Ash 2018 event analyzer – Losers edge out winners in year’s final major meeting
Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.
Ash 2018 – Bluebird faces Lentiglobin reckoning
The latest Lentiglobin data impress, but launch worries could clip Bluebird’s wings.
Ash 2018 – Luspatercept win puts Celgene’s deal making in a better light
Celgene’s deal-making skills have come under the microscope of late, but the group finally seems to have struck a good bargain with Acceleron and luspatercept.
Ash 2018 preview – smaller groups get their turn in the spotlight
Swedish Orphan Biovitrum made waves yesterday by getting its rare disease asset emapalumab into the Ash late-breakers – and bagging approval soon afterwards.
